# US 2026/0191914 A1 · Methods and compositions for reducing muscle loss and/or inhibiting sarcopenia associated with weight loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0191914 A1
- Document ID: US20260191914A1
- Status: Published application
- Kind: A1
- Application number: 19/558,906
- Filed: 2026-03-06
- Published: 2026-07-09
- Earliest claimed: 2023-09-12
- Assignees: Myos Corp.
- Applicants: Myos Corp.
- Inventors: Joseph MANNELLO
- Web page: https://patentgrep.com/patent/US20260191914A1

## CPC

- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for reducing muscle loss and/or inhibiting sarcopenia associated with weight loss in mammals via administration of a composition comprising an egg yolk derived product are disclosed. In one nonlimiting embodiment, the muscle loss and/or sarcopenia results from a weight loss drug such as semaglutide or tirzepatide.

## Claims

### Claim 1

A method for reducing muscle loss and/or inhibiting sarcopenia due to weight loss in a mammal, said method comprising administering to the mammal a composition comprising an egg yolk derived product.

### Claim 2 (depends on 1)

The method of claim 1 wherein the muscle loss and/or sarcopenia results from administration of a weight loss medication and/or low calorie diet.

### Claim 3 (depends on 2)

The method of claim 2 wherein the weight loss medication comprises semaglutide or tirzepatide.

### Claim 4 (depends on 1)

The method of claim 1 wherein the composition comprising the egg yolk derived product is administered once a day.

### Claim 5 (depends on 1)

The method of claim 1 wherein the composition comprising the egg yolk derived product is administered twice a day.

### Claim 6 (depends on 1)

The method of claim 1 wherein the composition comprising the egg yolk derived product is administered three times a day.

### Claim 7 (depends on 1)

The method of claim 1 wherein the composition comprising the egg yolk derived product comprises about 33% protein.

### Claim 8 (depends on 1)

The method of claim 1 wherein the composition comprising the egg yolk derived product comprises about 2 grams of protein per dose.

### Claim 9 (depends on 1)

The method of claim 1 wherein the composition comprises a fertilized egg yolk derived product.

### Claim 10 (depends on 1)

The method of claim 1 wherein the fertilized egg yolk derived product is FORTETROPIN.
